Search

Your search keyword '"Killick, S."' showing total 11 results
Start Over Author "Killick, S." Journal leukemia research
11 results on '"Killick, S."'

1. Identification of Aberrant Splicing Events in Myelodysplastic Syndrome Patients with Splicing Factor Gene Mutations

Author

Pellagatti, A., primary, Steeples, V., additional, Sharma, E., additional, Repapi, E., additional, Yip, B.H., additional, Armstrong, R.N., additional, Dolatshad, H., additional, Lockstone, H., additional, Taylor, S., additional, Giagounidis, A., additional, Vyas, P., additional, Papaemmanuil, E., additional, Woll, P., additional, Killick, S., additional, Malcovati, L., additional, Hellström-Lindberg, E., additional, Cazzola, M., additional, Smith, C.W.J., additional, and Boultwood, J., additional

Published
2017
Full Text
View/download PDF

2. 52 TARGETED RE-SEQUENCING ANALYSIS OF 31 GENES COMMONLY MUTATED IN MYELOID DISORDERS IN SERIAL SAMPLES FROM MYELODYSPLASTIC SYNDROME PATIENTS WITH DISEASE PROGRESSION

Author

Pellagatti, A., primary, Roy, S., additional, Di Genua, C., additional, Burns, A., additional, McGraw, K., additional, Larrayoz, M.J., additional, Fernandez-Mercado, M., additional, Valletta, S., additional, Mason, J., additional, Killick, S., additional, Mecucci, C., additional, Calasanz, M.J., additional, List, A., additional, Schuh, A., additional, and Boultwood, J., additional

Published
2015
Full Text
View/download PDF

7. C023 Expression profiling of CD34+ cells in patients with myelodysplastic syndromes: differences between early and advanced cases and analysis of apoptosis-related genes

Author

Pellagatti, A., primary, Cazzola, M., additional, Giagounidis, A., additional, Malcovati, L., additional, Della Porta, M.G., additional, Jädersten, M., additional, Killick, S., additional, Fidler, C., additional, Cattan, H., additional, Bowen, D., additional, Aul, C., additional, Hellström-Lindberg, E., additional, Wainscoat, J.S., additional, and Boultwood, J., additional

Published
2007
Full Text
View/download PDF

10. Low dose antithymocyte globulin for the treatment of older patients with aplastic anaemia.

Author

Killick SB, Cavenagh JD, Davies JK, and Marsh JC

Subjects
Aged, Anemia, Aplastic diagnosis, Antilymphocyte Serum adverse effects, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Immunosuppressive Agents adverse effects, Infusions, Intravenous, Male, Maximum Tolerated Dose, Middle Aged, Treatment Outcome, Anemia, Aplastic therapy, Antilymphocyte Serum administration & dosage, Immunosuppressive Agents administration & dosage
Abstract

We report 14 older patients with aplastic anaemia (AA) who were treated with 'low dose' antithymocyte globulin (ATG). The aims of the study were to assess the efficacy and safety of reduced dose ATG in patients over the age of 60 years. Median age was 71 years (range 62-74 years). At the study endpoint (response to treatment at 6 months) 12 patients were evaluable. All patients received lymphoglobuline (horse ATG; Genzyme) at a dose of 0.5vials/10kg/day for 5 days (5mg/kg/day, equivalent to one-third of the standard dose). There were no deaths attributed to ATG. Two patients died during follow-up, from sepsis and anaphylaxis following platelet transfusion, respectively. Only one of the 12 evaluable patients responded to treatment and remains transfusion independent at 14 months after ATG. These results suggest that this lower dose of ATG, though well tolerated, had low efficacy in the treatment of AA.

Published
2006
Full Text
View/download PDF

11. Thalidomide therapy for low-risk Myelodysplasia.

Author

Bowen D, MacIlwaine L, Cavanagh J, Killick S, Culligan D, Thomson E, and Mufti G

Subjects
Aged, Female, Humans, Male, Middle Aged, Risk, Antineoplastic Agents therapeutic use, Myelodysplastic Syndromes drug therapy, Thalidomide therapeutic use
Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results